ArticleScience advances2022

RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition.

Carolina Nunes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.